PEG–Polypeptide Block Copolymers as pH-Responsive Endosome-Solubilizing Drug Nanocarriers by Morton, Stephen Winford et al.
PEG−Polypeptide Block Copolymers as pH-Responsive Endosome-
Solubilizing Drug Nanocarriers
Mohiuddin A. Quadir,‡ Stephen W. Morton,‡ Zhou J. Deng, Kevin E. Shopsowitz, Ryan P. Murphy,†
Thomas H. Epps, III,† and Paula T. Hammond*
Department of Chemical Engineering and Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology,
Cambridge, Massachusetts 02139, United States
†Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19716, United States
*S Supporting Information
ABSTRACT: Herein we report the potential of click
chemistry-modiﬁed polypeptide-based block copolymers for
the facile fabrication of pH-sensitive nanoscale drug delivery
systems. PEG−polypeptide copolymers with pendant amine
chains were synthesized by combining N-carboxyanhydride-
based ring-opening polymerization with post-functionalization
using azide−alkyne cycloaddition. The synthesized block
copolymers contain a polypeptide block with amine-functional
side groups and were found to self-assemble into stable
polymersomes and disassemble in a pH-responsive manner
under a range of biologically relevant conditions. The self-
assembly of these block copolymers yields nanometer-scale
vesicular structures that are able to encapsulate hydrophilic cytotoxic agents like doxorubicin at physiological pH but that fall
apart spontaneously at endosomal pH levels after cellular uptake. When drug-encapsulated copolymer assemblies were delivered
systemically, signiﬁcant levels of tumor accumulation were achieved, with eﬃcacy against the triple-negative breast cancer cell
line, MDA-MB-468, and suppression of tumor growth in an in vivo mouse model.
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■ INTRODUCTION
Engineered nanoparticles with stimuli-responsive modalities
can substantially improve the therapeutic eﬃcacy of a drug by
targeting tumor-speciﬁc characteristics, such as hypoxia, for
localized delivery of the payload in the desired tissue. A vast
arsenal of such nanosystems of either polymeric, liposomal, or
micellar origin have been developed and reported following this
delivery strategy.1,2 The working principle of stimuli-responsive
drug delivery systems involves a structural or conformational
change of the nanocarriers in response to a cellular or
extracellular stimulus of chemical, biochemical, or physical
origin, resulting in the release of active species within a speciﬁc
biological environment. Stimuli-responsive nanoparticles pro-
vide a critical advantage in delivering payloads to a tissue of
interest, where the disease-speciﬁc characteristics of that tissue
promote drug release, thereby reducing oﬀ-target exposure to
the therapeutic agent.3,4
Among the wide range of biological signals unique to
diseased tissue, a change in pH is particularly interesting
because of the opportunity to leverage the many pH gradients
found in tissues and cellular compartments in both
physiological and pathological states.5,6 Exploitation of the
endosomal/lysosomal pH drop has become an established
route to improve intracellular delivery and to reduce
extracellular toxicity of an active drug that is either conjugated
to a polymer backbone through a pH-responsive linker or
encapsulated into a pH-responsive nanoparticle.7 Development
of facile, highly controlled fabrication techniques, along with
minimal immunogenicity, biodegradability, and clearance of the
component polymers, remain a challenge for clinical translation
of such pH-responsive systems.8
Utilization of a synthetic polypeptide incorporated in a block
copolymer with complementary hydrophilic and hydrophobic
properties is a promising approach to create self-assembled
nanoscale carriers for drug delivery with pH-responsive
properties. Stable secondary structures, long-term biodegrad-
ability of the peptide bond comprising the polymer backbone,
and biocompatibility are some of the attractive features of
synthetic polypeptides compared to those of traditional
polymers.9 Synthetic polypeptide-based homopolymers and
block copolymers are easily synthesized and provide a facile
route to generate hierarchical biocompatible self-assembled
superstructures equipped with diverse environmentally sensitive
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modalities suitable for biomedical applications.10−14 Previously,
our group reported a new strategy to synthesize poly(γ-
propargyl L-glutamate) (PPLG) by N-carboxyanhydride (NCA)
polymerization of propargyl-L-glutamate.15 These novel poly-
peptides contain pendant alkyne groups along the polypeptide
chain primed for a facile alkyne−azide cycloaddition (click)
reaction; the ability to click virtually any group onto a
polypeptide backbone in high density is unique to these
systems.16 In subsequent reports, we described the synthesis of
a poly(ethylene glycol)-b-PPLG system, in which amine-
terminated poly(ethylene glycol) (PEG) was used as an
initiator for ring-opening polymerization of the glutamate
NCA, thereby creating an amphiphilic block copolymer.17 By
reacting the pendant alkyne side chains on the PPLG backbone
with amino-functionalized azides, a library of pH-responsive
macromolecules was developed that demonstrates strong
buﬀering capacity with a pH-dependent solubility phase
transition in water. These copolymers can aggregate to form
stable self-assembled colloids under physiological conditions
that remain intact in blood circulation and within the
extracellular spaces (pH 7.00−7.45) but that rapidly destabilize
under endosomal or highly acidic tumor hypoxic conditions to
release a drug payload (early endosome pH 5.5−6.3 and late
endosome pH < 5.5). Here, we investigate both the ability of
these novel architectures to self-assemble and disassemble in a
pH-responsive fashion and examine the eﬀects of this
nanocarrier behavior on drug encapsulation and release
characteristics in cellular environments. We demonstrate the
use of these assemblies as pH-responsive drug delivery systems
with optimal pH-controlled stability and release in vitro.
Furthermore, we translate these systems to an in vivo murine
xenograft model in which we probe the biodistribution, tumor
localization, and drug delivery capabilities of these self-
assembled carriers toward tumor remediation.
■ RESULTS AND DISCUSSION
Polypeptide-based self-assembled systems have established
themselves as a potential class of drug delivery vehicle, due,
in large part, to their stability in systemic circulation and their
ability to break down into resorbable amino acids.18,19 To
fabricate polyelectrolyte block copolymers that self-assemble to
form pH-responsive nanoparticles, we initiated the ring-
opening polymerization of PPLG NCA according to our
previous reports,15,17,20,21 using amine terminal PEG initiators
of two diﬀerent molecular weights, 5 and 10 kDa, to create
PEG-b-PPLG block copolymers. In subsequent steps, we
modiﬁed the PPLG block of PEG-b-PPLG with two diﬀerent
azido-functionalized tertiary amines, namely, diisopropylamine
and diethylamine, by copper catalyzed azide−alkyne cyclo-
addition, generating copolymers 1−4. The synthetic route to
the copolymers is presented in Scheme 1. The eﬃciency of the
click reaction and the attachment of the amine pendant side
chains to the polypeptide backbone were conﬁrmed by 1H and
13C NMR spectra that match with our previously reported
synthesis.17 The dispersity of the synthesized copolymers was
typically within the range of 1.11−1.16 (Table 1 of the
Supporting Information). We chose doxorubicin as a
representative chemotherapy drug for assessing encapsulation
and release characteristics from these colloidal systems because
of the well-deﬁned pharmacological role of the drug in treating
several types of cancer and because of its ease of character-
ization under in vitro and in vivo conditions.
After synthesis of the copolymers, our initial work focused on
demonstrating the pH-dependent assembly and disassembly of
Scheme 1. Synthetic Route to the pH-Responsive Copolymersa
aDoxorubicin is used as the model cytotoxic drug.
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the PEG-b-PPLG copolymers with amine pendant side chains.
To that end, critical aggregation concentration (CAC)
measurements of the copolymers were performed at four
diﬀerent pH values ranging from 5.5 to 8.0, evaluated by
ﬂuorescence spectroscopy using a pyrene probe (Table 1).
We found that PEG 5 kDa-based copolymers (1−2) were
characterized by CAC values an order of magnitude lower than
PEG 10 kDa-b-PPLG copolymers (3−4), indicating more
stable assembly of the PEG 5 kDa-b-PPLG systems. This
ﬁnding can be attributed to the increased hydrophilicity and
longer length of the PEG 10 kDa chain, which reduces the
driving force for assembly. None of the block copolymers
exhibited any association at pH 5.5, indicating that the
copolymers are able to self-assemble into nanostructures at
moderate to high pH but destabilize and disassemble at acidic
pH to become unimers as the amines become fully
protonated.17
Having established the fact that copolymers 1−4 show pH-
dependent association, we investigated the physical properties
of the hierarchical structure that these copolymers form in an
aqueous environment. Facile self-assembly of the copolymers
was carried out by dissolving 10 wt % of material in DMSO
followed by addition of pH 8.0 buﬀer and subsequent dialysis
using a cellulose membrane with a MWCO of 3.5 kDa against a
buﬀer of similar pH for 24 h. The dialyzed solution was passed
through a 0.45 μM ﬁlter prior to further analysis. Figure 1
illustrates the self-assembly properties of the copolymers after
dialysis and ﬁltration. With dynamic light scattering (DLS), it
was found that all the copolymers formed nanostructures with
characteristic sizes from 110 to 180 nm. The size of the
nanoparticles was strongly related to the PEG molecular weight
and the pendant amino group side chains (Figure 1a). Recent
work has suggested that the morphology of polypeptide-based
block copolymer self-assembled structures is not only depend-
ent on the molecular composition but also, to a larger extent,
on the kinetic trapping of the system induced by the rigidity of
the α-helical hydrophobic peptide segment during the solvent
diﬀusion process.22 Transmission electron microscopy (TEM)
of copolymer 3 (unstained and air-dried on a grid from a
solution of nanoparticles at pH 8.0) shows nanoparticles with
vesicle-like structures (Figure 1d). (A cryo-TEM image of the
vesicles formed from block copolymer 2 is presented in
Supporting Information S1a.) We further conﬁrmed the
vesicular assembly of the PEG−PPLG pH-responsive vesicles
using static light scattering (SLS). The factor ρ = RG/RH was
calculated for copolymers 1−4 from measured values of the
radius of gyration (RG) and radius of hydration (RH).
22 This
value was found to be within the range of 1.02−0.87 (ρ value
Table 1. Critical Aggregation Concentration of Copolymers
1−4 at Diﬀerent pH Values
critical aggregation concentration [M]
pH copolymer 1 copolymer 2 copolymer 3 copolymer 4
8.0 7.38 × 10−8 7.23 × 10−8 7.44 × 10−7 8.22 × 10−7
7.4 7.18 × 10−8 7.30 × 10−8 8.07 × 10−7 8.23 × 10−7
6.5 n/aa n/a 7.46 × 10−5 5.82 × 10−5
5.5 n/a n/a n/a n/a
an/a, not available.
Figure 1. (a) Eﬀect of PEG molecular weight on the hydrodynamic diameter of amine-substituted PEG−polypeptide block copolymer. (b) Eﬀect of
serum and salt concentration on the self-assembly of block copolymer 1. (c) Eﬀect of pH on the polydispersity index of amine-substituted PEG−
polypeptide assemblies made of block copolymers 2 and 4. (d) TEM image of the vesicles synthesized with copolymer 1 at pH 8.0 with a polymer
concentration of 1 mg mL−1. The scale bar for the TEM image is 200 nm.
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0.733 indicates spherical micellar structures and 1.0 indicates
vesicular bilayer constructs). The particles were stable for >1
month in PBS containing 180 mM NaCl, with increased size
upon exposure to 10% FBS (Figure 1b for 80 h time period at
room temperature). In PBS, the particle size does not change
drastically upon elevating the temperature to 37 °C
(Supporting Information S1b). The polydispersity indices
(PDI) of the vesicles were <0.2 for all 1−4 block copolymer
systems.
The buﬀering behavior and pH responsiveness of the PEG−
PPLG copolymers with amine pendant chains were investigated
with systematic pH titration and Förster resonance energy
transfer (FRET)-based experiments. Titration was performed
on all four copolymers; the material was dissolved in 125 mM
NaCl to partially screen the positive charges on the backbone,
and then the pH was gradually increased from 3 to 10.
Representative titration curves of copolymers 1 and 2 are
presented in Figure 2a. All of the block copolymers under
investigation demonstrated a strong buﬀering capacity from pH
5.5 to 7.7. The pH-induced solubility transition with the
addition of acid/base depended strongly on the side chain
amine groups, which provide segmental charge repulsion and
water solubility.17 Furthermore, to understand the assembly−
disassembly behavior of these systems, a FRET experiment was
designed to investigate the pH-responsive property of the
vesicles formed from copolymers 1−4 (Figure 2c). Utilization
of a FRET-associated dye couple is a strategy recently used to
investigate the stability of micellar assemblies;23 in a recent
publication, we have shown the ability to use this method to
determine the in vivo stability of micelles following intravenous
injection in mice.24 Two ﬂuorophores that are known to form a
FRET pair, namely, a Cy5.5 azide and a Cy7 azide, were
separately conjugated to approximately 0.1 mol % of unreacted
alkyne group present in the PPLG block of an individual
copolymer. Then, the Cy5.5 and Cy7 copolymers were blended
in solution to form vesicles where FRET coupled dyes are
located within the Förster distance. This assembly was achieved
by increasing the pH to deprotonate the tertiary amine-
containing PPLG block, making it hydrophobic in nature and
enabling its self-assembly into nanosized vesicles with the
PPLG-amine blocks located in the hydrophobic interior of a
vesicular bilayer. The resulting aggregation of the ﬂuorophores
brings them within the FRET distance, and excitation of the
donor dye at 640 nm causes a ﬂuorescent emission in the FRET
channel (800 nm). At lower pH values, the amine groups of the
PPLG block become protonated and positively charged, causing
vesicular destabilization and substantial reduction in FRET
emission because of the increased distance between constituent
copolymers that are now free in solution. In comparison, when
a pH-nonresponsive copolymer functionalized with butyl
benzene was subjected to the same set of experiments, it did
not show this pH-dependent reduction of ﬂuorescence
emission at lowered pH (Figure 2b).
After establishing the fact that PEG−PPLG copolymers are
able to self-assemble into pH-responsive vesicles, we inves-
tigated their drug entrapment and release characteristics using
doxorubicin, a weak amphipathic water-soluble drug molecule
with pKa = 8.3, as the model drug. Generally, the encapsulation
Figure 2. Investigation of pH-responsive properties of representative PEG−polypeptide copolymers. (a) pH titration curve of copolymers 1 and 2.
(b) Reduction of relative FRET eﬃciency upon lowering the pH from 7.4 to 4.5. (c) Principle of the FRET experiment carried out by forming a
vesicle constituted from the respective copolymer tagged with the Cy5.5 and Cy7 FRET pair.
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of doxorubicin within the polymer vesicle core is promoted by
applying an ionic or pH gradient across the vesicle
membrane.25−27 We have adapted the protocol from
Lecommandoux et al. for encapsulation of doxorubicin within
block copolymer vesicles.28 For the purpose of drug
encapsulation, both the copolymer and doxorubicin were
dissolved in DMSO followed by gradual and dropwise addition
of the DMSO solution to pH 8.0 buﬀer that was subsequently
(time scale of no more than 20 s) introduced to a dialysis
medium containing PBS (pH 7.4). The ﬁnal copolymer
concentration was maintained at 2 mg mL−1. After 4 h of
dialysis against 10 mM PBS, the doxorubicin loading in vesicles
was quantiﬁed by UV−vis spectroscopy, and drug release was
measured by a dialysis method at two diﬀerent pH values (PBS
of pH 7.4 and 5.5) under sink conditions (37 °C, with constant
agitation). In the case of drug encapsulation, it was found that
vesicles formed from copolymers 1 and 2 were able to
encapsulate 33 and 30% of the added quantity of doxorubicin
(i.e., encapsulation eﬃciency), with a ﬁnal loading content of 20
and 15% by weight, respectively. Vesicles constituted from
copolymers 3 and 4 were able to retain 34 and 31% of the
doxorubicin added initially to the copolymer solution during
encapsulation; the ﬁnal loading of these vesicles is 12 and 10%
by weight, respectively. In terms of doxorubicin loading, the
PEG−PPLG-based vesicles exceed PEO-b-polycarbonate block
copolymer vesicles29 and parallel that of other NCA-derived
polypeptide block copolymer micellar30 and vesicular31
assemblies.
The cumulative release proﬁle of loaded doxorubicin from
PEG 10 kDa-based vesicles (constituted from copolymer 3)
showed pH-dependent release between pH 7.4 (PBS) and pH
5.5 (Figure 3a). However, under both of these release
conditions, an initial burst release of 40% of total doxorubicin
was evident. This burst was followed by a slow release of the
drug in PBS, with a more controlled release of drug at pH 5.5.
In contrast, the vesicles constituted from PEG 5 kDa-based
copolymer 1 released only 20% of entrapped drug after 25 h at
pH 7.4 (PBS) and exhibited almost quantitative and sustained
release of doxorubicin at pH 5.5 (Figure 3b). In our case, the
prominent acceleration of release at pH 5.5 can be attributed to
well-reported 3′-NH2 protonation of the doxorubicin coupled
with the protonation of the tertiary amines along the PPLG
segment at lower pH, resulting in expulsion of the drug cargo
from the vesicle interior.30 The diﬀerences in release behavior
between PEG 10 kDa- and 5 kDa-based systems can be
attributed to the comparatively reduced stability of the former,
as evident from the higher CAC values of copolymer 3
compared to that of 1. At pH 7.4, doxorubicin release kinetics
Figure 3. Cumulative release proﬁle of doxorubicin loaded into vesicles formed from (a) copolymer 3 and (b) copolymer 1 in PBS (pH 7.4) and at
acidic pH (5.5).
Figure 4. Confocal ﬂuorescence microscopic images of MDA-MB-468 cells treated with doxorubicin-loaded vesicles of copolymer 1 (upper panel)
and cells cotreated with the vesicles and 10 μM chloroquine (lower panel) for 2 h at 37 °C. Doxorubicin ﬂuorescence was visualized by excitation at
480 nm and emission at 560 nm.
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was mainly controlled by solubilization of the hydrophobically
stabilized drug from the membrane assembly of the PPLG
block followed by diﬀusion through the outer PEG layer.
Nanoparticles normally enter cells through endocytosis, and
while contained in the endosomal compartment, they undergo
an environmental pH decrease from early to late endosomes.
To examine the eﬀect of the pH responsiveness on doxorubicin
release within the intracellular environment, we treated MDA-
MB-468 human breast cancer cells with the vesicles and
investigated the intracellular traﬃcking of doxorubicin by
confocal microscopy. After 4 h of incubation with doxorubicin-
loaded vesicles, the free drug was found to traverse to the
nucleus (Figure 4, upper panel). The data suggested that the
pH-responsive vesicles were disrupted by the endosomal pH
drop; doxorubicin was released from the vesicles and
subsequently diﬀused into the nucleus where it could bind to
DNA. When the cells were cotreated with chloroquine, which is
a weak base that buﬀers the endosomal pH and prevents it from
lowering, intracellular doxorubicin was found to accumulate in
the cytoplasm in punctate form, contained within the
endosomal vesicles, without any translocation to the nucleus
(Figure 4, lower panel). This result suggests that the vesicles
remain intact inside the endosomes, which is consistent with
the pH-responsive properties of the vesicles in the intracellular
environment.31,32
Next, we assessed the eﬃcacy of the encapsulated
doxorubicin in four diﬀerent vesicular formulations. MDA-
MB-468 cells were treated with increasing concentrations of
vesicle-loaded doxorubicin for 3 days at 37 °C (Figure 5A), and
cell viability was measured at the end of the treatment to
generate IC50 values for each of the tested formulations.
Doxorubicin-loaded vesicles synthesized from copolymers 1, 2,
3, and 4 showed IC50 values of 0.85, 0.38, 0.86, and 0.47 μM,
respectively. In comparison, free doxorubicin gave a lower IC50
value of 0.27 μM. The cytotoxicity of empty vesicles also was
assessed, as shown in Figure 5B. The vesicles without
doxorubicin were found to be nontoxic to cells within the
relevant drug-encapsulated vesicle concentration range. At
higher concentrations, vesicles fabricated from copolymers 2
and 4 were found to be more cytotoxic than those prepared
from 1 and 3, which is most likely due to the reduced shielding
of the tertiary amino group by aliphatic side chains.
To assess the in vivo stability of the vesicles synthesized from
polypeptide-based systems, we used FRET association of Cy5.5
and Cy7 dye-conjugated PEG-b-PPLG copolymers using our
previously published approach.24 Copolymer 1 tagged with this
FRET dye pair was mixed in stoichiometric proportions at pH
8.0. The solution was dialyzed against PBS at pH 7.4 for 4 h to
induce self-assembly. The design of the experiment was
motivated from the fact that the dissociation of the vesicles
will increase the distance between donor and acceptor dyes,
hence reducing the ﬂuorescent intensity in the FRET channel
(λex = 640 nm; λem = 800 nm) and increasing the intensity in
the donor channel (λex = 640 nm; λem = 700 nm) and thereby
Figure 5. Assessment of eﬃcacy of vesicle-loaded doxorubicin in MDA-MB-468 cells. (a) Concentration-dependent inhibition of four diﬀerent
formulations of vesicles on tumor cell growth. Free doxorubicin was used as a control. (b) Cytotoxicity of the empty vesicles. The concentrations of
the vesicles were normalized to their corresponding doxorubicin loading in panel a. The experiments were performed in triplicate, and data are
presented as the mean ± standard deviation.
Figure 6. (A) Copolymer 1 vesicle stability on the basis of FRET association of the carrier components following systemic administration in non-
tumor-bearing BALB/c mice. Top panel corresponds to λex = 640 nm and λem = 700 nm (donor channel), and bottom panel corresponds to λex =
640 nm and λem = 800 nm (FRET channel). (B) Biodistribution quantitation in necropsied tissue (Li, liver; S, spleen; K, kidneys; H, heart; and Lu,
lungs) 24 h following systemic administration in BALB/c mice in both the donor and FRET channels. Fluorescence recovery from harvested tissue
includes the background subtraction of tissue from an untreated control for removal of autoﬂuorescence. The resultant quantiﬁcation is normalized
to the injected dose, based on the ﬂuorescence intensity of the injected dose following IVIS imaging of the vial pre-injection.
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provide a visual and quantiﬁable readout of the intact vesicle
during systemic circulation. The vesicles were systemically
administered in BALB/c mice at an injection volume of 0.1 mL
at polymer concentrations of 1 mg/mL. The initial pre-
injection FRET eﬃciency of the vesicular formulation in PBS
(ex vivo, IVIS, Xenogen) was calculated to be 92%.
Biodistribution (Figure 6A,B and Supporting Information
Figure S2) and circulation persistence readouts were generated
by whole-animal ﬂuorescence imaging, as well as quantiﬁcation
of ﬂuorescence recovery from live-animal blood samples
obtained retro-orbitally, in both the donor (λex = 640 nm;
λem = 700 nm) and FRET channel (λex = 640 nm; λem = 800
nm). The upper panel of Figure 6A shows the donor channel,
indicating that dissociated donor-labeled copolymer cleared
fairly rapidly, likely because of its positive charge. The donor
ﬂuorescence contributions could additionally be due to swelling
or size increase of the vesicles under stress in the systemic
biological in vivo environment, although we believe this
contribution to be minimal relative to complete dissociation
of the micellar structure. The lower panel of Figure 6A
illustrates that the associated vesicles are quite stable (higher
FRET eﬃciency, data shown in the Supporting Information)
and remain in the bloodstream at appreciable levels for up to 24
h. The persistence characteristics in serum, shown in Figure S3
(Supporting Information), correspond to that of the blood
sampled at the time points indicated (Figure 6A). FRET
eﬃciency of isolated serum was obtained from these data. This
eﬃciency was calculated as the ratio of total FRET radiant
eﬃciency to the total radiant eﬃciency in the donor and FRET
channels following background subtraction of whole-animal
autoﬂuorescence in the respective channels. These images and
the quantiﬁed data convey a real-time assessment of these
systems as delivery vectors, with pharmacokinetic data on the
ability of these systems to remain intact in the bloodstream
collected simultaneously with a clearance proﬁle for both
destabilized and intact micelles. A rapid destabilization and
clearance was noted upon systemic administration (clearing
nearly 60% injected dose (ID) from circulation within 30 min
and FRET eﬃciency of 12% for those remaining in the
bloodstream); however, a signiﬁcant fraction was retained in
blood (6%) after 24 h with a high FRET eﬃciency (42%). After
24 h, it was found that 21% ID distributed to the liver and 8%
to the kidneys (on the basis of FRET), with minimal fractions
detected in other relevant organs (Figure 6B). Similar liver
accumulation has been widely reported across the broad
architectural spectrum of synthetic nanoparticles. For instance,
transferrin-conjugated pegylated gold nanoparticles reported by
Choi et al. showed that 17−21% of the initial ID accumulated
in the liver, whereas typical NCA-derived polypeptide block
copolymer polymersomes, such as a poly(γ-benzyl L-gluta-
mate)-b-hyaluronan-based system, showed liver accumulation
of 36.54 ± 4.13% ID (per gram of tissue) after 1 h and
approximately 33% ID after 24 h, as traced by radioactivity of
99mTc in Balb/C mice at a 5 mg/kg tail vein injection.33,34
After investigating the pharmacokinetics of the carrier based
on copolymer 1 in BALB/c mice, we sought to understand the
potential of these systems to deliver therapeutics to solid
tumors. Using a model with immune-compromised NCR nude
mice with established xenografts, we expected the biological
performance of the carrier to facilitate delivery to solid tumors
for therapy. Investigation of tumor localization of the FRET-
assembled system showed signiﬁcant accumulation in the hind
ﬂank tumor xenografts 24 h following systemic administration,
displayed in Figure 7A. On the basis of quantiﬁcation of the
FRET-based ﬂuorescence increase post-administration after 24
h, 3% ID localized in the tumor. On the basis of donor
ﬂuorescence, 2% ID was observed to be localized in the tumor.
In total, 5% ID of the total micelles administered, both
destabilized and intact, was found to accumulate, presumably
via the enhanced permeation and retention (EPR) eﬀect, in the
MDA-MB-468 xenografts. This number is similar to the extent
of tumor accumulation exhibited by transferrin-mediated
actively targeted gold nanoparticles, where the tumor amassed
2 to 3% of the ID in mice bearing s.c. Neuro2A tumors.33 It is
anticipated that with the use of targeting ligands that enhance
uptake, greater accumulation can be achieved with these
nanoparticle systems.
Complementary bioluminescence imaging displays the
established tumor, with corresponding ﬂuorescence biodistri-
bution data shown to the right, visibly conﬁrming localization
of the vesicles in the tumors as well as the anticipated
accumulation in liver.
To interrogate the remediation potential of this system,
luciferase-expressing MDA-MB-468 xenografts were established
Figure 7. (A) Biodistribution of tumor-bearing nude mice at 24 h post-systemic administration. The left image corresponds to the luminescence of
the tumor cell line (MDA-MB-468). The image in the midpanel corresponds to ﬂuorescence imaging of NPs at λex = 640 nm and λex = 700 nm
(donor channel), and the right image corresponds to ﬂuorescence imaging of NPs at λex = 640 nm and λex = 800 nm (FRET channel). (B) Tumor
remediation study against MDA-MB-468 xenografts in NCR nude mice, comparing untreated free-doxorubicin-treated and dox-loaded PEG−PPLG
systems treated groups. Data normalized to pre-injection tumor luminescence show a temporally resolved fold change in tumor-speciﬁc
luminescence signal.
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prior to treatment (Figure S4, Supporting Information). The
development of these tumors was tracked via live-animal
luminescence imaging prior to the systemic administration of
1.5 mg/kg doxorubicin-loaded PEG−PPLG vesicles with three
repeated doses at days 0, 10, and 14 following determination of
established, progressing solid tumors. As shown in Figure 7B,
this treatment regimen reduced tumor growth, whereas the
untreated control exhibited exponential growth during this time
period. Data are shown as fold luminescence change
normalized to pre-injection tumor radiance (based on
luminescence imaging of the luciferase-expressing cells).
Comparison of days 10 and 20 shows diﬀerences in fold
luminescence change from the initial tumor size, with the
treated group characterized by an average fold change of 0.95
and 1.26 relative to 3.10 and 3.54 for the untreated group (each
group is normalized to the tumor-speciﬁc luminescence prior to
treatment). This observation holds promise considering the fact
that tumor growth reduction was achieved at a lower dose (1.5
mg/kg, three doses) than previously reported polypeptide-
based doxorubicin polymersomes, for which 5 mg/kg (single
dose) was required to delay the doubling time of tumor
growth.34
■ CONCLUSIONS
We have shown that novel PEG−polypeptide copolymers with
amine pendant chains can be utilized as a pH-responsive drug
delivery vehicle. These copolymers can self-assemble as vesicles
that are eﬀective systemically administrable drug carriers.
Furthermore, the vesicles are able to encapsulate therapeutically
signiﬁcant quantities of drug and to release them in a pH-
dependent manner in the intracellular environment. We also
have demonstrated that these nanosized vesicles are stable
platforms for delivery and can successfully localize in solid
tumors and release doxorubicin, mediated by the enhanced
permeation and retention eﬀect and the lowered pH of the
tumor microenvironment. When loaded with doxorubicin, the
vesicles were found to reduce tumor growth, whereas the
untreated control tumors continued to grow exponentially.
Currently, we are investigating the eﬀect of diﬀerent hydro-
phobic and hydrophilic segments of the constituent block
copolymers on in vivo residence time, and we are exploring the
targeting and drug delivery eﬃcacy of the vesicles in tumor-
bearing animal models. It is anticipated that these systems can
be labeled with molecular targeting ligands that further enhance
tumor speciﬁcity while lowering uptake in other parts of the
body.
■ METHODS AND MATERIALS
Synthesis of PEG−Polypeptide Block Copolymer with
Alkyl Amine Side Chains. The synthesis of PEG−-
polypeptide block copolymer was carried out by previously
described methods.17 As a representative example of PEG5K−
PPLG copolymer (1), ﬁrst, γ-propargyl L-glutmate was
prepared by esteriﬁcation of L-glutamic acid with propargyl
alcohol using TMSCl (trimethylsilyl chloride) as the coupling
agent. L-Glutamic acid (20.6 g, 140 mmol, 1.0 equiv) was ﬁrst
suspended in propargyl alcohol (31.0 g, 140 mmol, 1.0 equiv),
and the reaction mixture was cooled to 0 °C. Then, TMSCl (38
g, 350 mmol, 2.5 equiv) was added dropwise, and the reaction
was allowed to run for 48 h under a nitrogen environment. The
resultant product, propargyl L-glutamate, was puriﬁed by
precipitation of the reaction mixture in diethyl ether followed
by ﬁltration. In the second step, propargyl-L-glutamate was
converted to its corresponding N-carboxyanhydride by the well-
established Fuchs−Farthing method, whereby propargyl L-
glutamate (5.1 g 23 mmol, 1.0 equiv) was decarboxylated by
triphosgene (2.61 g, 8.7 mmol, 0.38 equiv). The ring-opening
polymerization of the resulting propargyl L-glutamate NCA (3.8
g, 18.3 mmol, 25 equiv) was initiated with amine-terminated
poly(ethylene glycol) of diﬀerent molecular weights (MW 5K
and 10K) under a nitrogen atmosphere. The polymerization
reaction was allowed to continue for 72 h, after which the
resulting poly(ethylene glycol)-b-poly(γ-propargyl L-glutamate)
(PEG-b-PPLG) was puriﬁed by repeated precipitation in
diethyl ether and water. Two types of azide-modiﬁed amine
side chains, diisopropylamine and diethylamine, were con-
jugated to the polymer backbone by a Cu-mediated azide−
alkyne click cycloaddition reaction. As a typical example of a
click cycloaddition reaction, a PEG-b-PPLG block copolymer
(1.7 g, 2.3 mmol, 1.0 equiv of alkyne repeat units) was
dissolved in anhydrous DMF, into which azide-terminated
amines (2.0 g, 3.5 mmol, 1.5 equiv of alkyne repeat units) and
PMDETA (0.2 g, 1.2 mmol, 0.5 equiv) were successively added.
The resulting solution was degassed by bubbling nitrogen
through the solution for 10 min, after which CuBr (0.172 g, 1.2
mmol, 0.5 equiv) was added. The reaction was allowed to run
at room temperature under nitrogen atmosphere for 48 h, after
which the solvent was evaporated, and the residue was
dissolved in acidiﬁed water and treated with dowex M1341
for 15 min. After removal of the dowex beads by ﬁltration, the
solution was dialyzed against acidiﬁed water (pH < 5.0) for 24
h followed by dialysis against Milli-Q water. After freeze-drying,
the ﬁnal polymer was obtained as an oﬀ-white solid with an
overall yield of 65%. Spectral data match with those of
previously reported compounds.15,17
Fabrication and Characterization of Block Copolymer
Vesicles. The block copolymer vesicles were fabricated by a
diaﬁltration method as previously reported.22,28 Brieﬂy, 30 mg
of amine-substituted PEG-b-PPLG was ﬁrst dissolved in 1 mL
of DMSO with stirring for 30 min. Then, the solution was
added dropwise to 2 mL of phosphate buﬀer at pH 8.0 with
stirring. The resulting mixture was stirred at room temperature
for another 1 h, after which it was dialyzed against pH 8.0 buﬀer
for 48 h to promote self-assembly. The dialysis medium was
changed every 4 h for the ﬁrst 12 h. The concentration of the
polymers after dialysis was 6 mg/mL. The dialyzed self-
assembled vesicles suspension was ﬁltered through 0.45 μm
polyether sulfone ﬁlters and analyzed using dynamic light
scattering (DLS; Malvern Instruments Ltd., UK) to determine
particle size. For multiangle light scattering measurements, a
Brookhaven instrument was used at scattering angles of 30 to
150° with a 1 min measurement time/sample. The cumulant
analysis method (DLS) was used to determine the hydro-
dynamic diameter and polydispersity of the vesicles, and static
light scattering (SLS) was used to determine the radius of
gyration (RG). TEM images were captured with a JEOL 2010
advanced high-performance TEM at an acceleration voltage of
200 keV. Samples were prepared by drop-casting 2 μL of a 10
mg/mL vesicle suspension onto a carbon-coated 200 mesh
copper grid. Cryo-TEM images were captured using a Tecnai
G2 12 Twin TEM operating at 120 kV, with a sample probe
temperature below −176 °C during imaging. Samples were
prepared using an FEI Vitrobot at 22 °C and 100% relative
humidity. A 3 μL sample volume was pipetted onto plasma-
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etched Quantifoil R 2/1 grids prior to blotting and subsequent
vitriﬁcation in liquid ethane.
Acid−Base Titration and Assessment of pH-Depend-
ent Aggregation Behavior. Acid−base titration was
performed by gradual change of pH from 3 to 10 through
the incremental addition of 0.1 M NaOH according to
published procedures.32,35 Amine-substituted PEG-b-PPLG
copolymers were dissolved in 3 mL of 125 mM NaCl solution,
with an amine concentration equivalent of 10 mM. The pH of
this solution was reduced to 3.0 using 1 M HCl. The titration
was carried out by adding 10 mL aliquots of 0.1 M NaOH to
the resulting acidic solution of PEG-b-PPLG and measuring the
pH after every addition. To determine the pH-dependent
aggregation behavior, critical association concentration (CAC)
values of the diblock copolymers were measured spectroﬂuoro-
metrically as a function of pH using the pyrene probe method.
A stock solution of pyrene in acetone (6.5 × 10−5 M) was
prepared, and 10 μL aliquots were added to glass vials. After
allowing the acetone to evaporate, polymer solutions at
diﬀerent concentrations prepared in pH 5.5, 6.5, 7.4, and 8.0
buﬀers were added to the vials and left to equilibrate overnight.
The ﬁnal concentration of pyrene in the working solution was
kept at 6.5 × 10−7 M. The ratio of the peak intensities of
ﬂuorescence emission (373/384 nm) was used to determine
the CAC as a function of pH. Fluorescence spectroscopy was
carried out on a Horiba Fluorolog spectroﬂuorimeter at room
temperature. For FRET-based assessment of pH-dependent
aggregation−disaggregation, Cy5.5- and Cy7.0-conjugated pH-
responsive block copolymers were ﬁrst synthesized by attaching
azide-terminated dyes to unreacted alkyne side chains (0.1 mol
%) by copper-mediated click chemistry. Dye-labeled vesicles
were ﬁrst dissolved in phosphate buﬀer of pH 8.0 with a ﬁnal
block copolymer concentration of 5 mg/mL. The stock
solution was diluted with 0.2 M citric−phosphate buﬀer to
diﬀerent pH values, keeping the ﬁnal polymer concentration
ﬁxed at 1 mg/mL. A pH-nonresponsive block copolymer
(PEG-NH2 initiated PPLG block copolymer with aromatic side
chains) was used as control. The solutions were excited at 640
nm, and emission spectra were collected from 780 to 810 nm
with excitation slits at 5 nm. The emission intensity at 800 nm
was used to determine the pH-responsive aggregation behavior
of the block copolymer assembly.
Doxorubicin Loading and Release Experiment. The
loading of doxorubicin into the vesicles was performed as
previously described,28 and their pH-dependent release
behavior was assessed following a previously reported
protocol.28 Brieﬂy, 10 mg of block copolymer was codissolved
with a speciﬁc amount of doxorubicin in 0.5 mL of DMSO. The
organic phase was gradually and dropwise added to phosphate
buﬀer of pH 8.0 with stirring followed by rapid transfer to a
dialysis bag immersed in PBS (pH 7.41, ionic strength 150
mM). To remove the excess drug and DMSO, dialysis was
carried out using a membrane with a MWCO of 3.5 kDa for 4 h
at 30 °C. Drug loading content was quantiﬁed by measuring the
absorbance at λmax = 488 nm in PBS with the use of a
calibration curve. The loading eﬃciency is generally expressed
as the percent mass of doxorubicin in vesicles relative to the
mass of doxorubicin in the initial solution, and loading content
is expressed as the percent mass of doxorubicin in vesicles
relative to the mass of the block copolymer. For the release
experiments, spectra/Por 10 kDa MWCO ﬂoat-a-lyzers (1 mL
volume) were loaded with 1 mL of a doxorubicin-containing
vesicle suspension. The ﬂoat-a-lyzer arrangement was either
introduced to 25 mL of PBS (pH 7.4) or, for release
experiments at pH 5.5, the content within the dialysis container
was acidiﬁed to pH 5.5 and then immersed in 25 mL of dialysis
medium composed of pH 5.5 acetate buﬀer (10 mM acetate,
ionic strength 150 mM). With the maintenance of sink
conditions by replacing 2 mL of the dialysis medium with fresh
medium, the residual drug was measured by taking an aliquot
from inside the dialysis bag and measuring absorbance at λmax of
488 nm. The percentage of drug release was calculated from the
following equation:28
= − ×
⎛
⎝⎜
⎞
⎠⎟
t
t
% drug release 1
absorbance( )
absorbance( )
100
0
In Vitro Experimentation. Cytotoxicity Studies. MDA-
MB-468 triple-negative breast adenocarcinoma cells (ATCC)
were used in our experiments and grown in DMEM media
supplemented with 10% fetal bovine serum, 50 units/mL
penicillin, and 50 units/mL streptomycin.
Cytotoxicity assays were performed using the CCK-8
cytotoxicity assay (Sigma). Brieﬂy, cells were seeded in a 96-
well plate at 30% conﬂuence, and after 24 h, they were treated
with the vesicles at various concentrations. After 3 days of
incubation, the cell medium was replaced with fresh serum-free
OptiMEM medium containing 10% v/v of the CCK-8
proliferation reagent. After 2 h of incubation at 37 °C, the
absorbance at 450 nm was measured by a plate reader. Cell
viability was normalized to an untreated control and calculated
using a standard curve. To study the eﬃcacy of doxorubicin-
containing vesicles, the data were ﬁt with a dose-dependent
inhibition curve using Prism 5 (GraphPad).
Confocal Microscopy. Cellular uptake of PEG−PPLG
vesicles was assessed by confocal ﬂuorescence microscopy.
The confocal microscope images were taken using a Nikon A1R
ultra-fast spectral scanning confocal microscope (Nikon
Instruments Inc., Melville, NY). Cells were seeded in
CELLview glass-bottom dishes (Greiner Bio-One GmbH,
Germany) at 1 × 105 cells per well and grown overnight.
Then, cells were incubated with the vesicles at 37 °C in DMEM
complete medium for 24 h. At the end of this period, cells were
washed followed by addition of DAPI for an additional 10 min,
after which they were further washed with PBS and imaged.
In Vivo Experimentation. FRET Stability Studies. FRET
assembled PEG−PPLG vesicles were systemically administered
in BALB/c mice (0.1 mL via tail vein injection) at a
concentration of 1 mg/mL (FRET radiant eﬃciency = 1 ×
109). Temporally resolved biodistribution imaging was
performed using an IVIS live-animal ﬂuorescence imaging
system at both the speciﬁed donor and FRET channels
(Xenogen, Caliper Instruments). Quantiﬁcation of radiant
eﬃciency was performed by drawing regions of interest around
the collected blood samples using Living Image 4.0 software
(Caliper). Data presented as the percent ID were determined
by quantifying total radiant eﬃciency of the injected sample
(determined by imaging prior to administration) and
calculating the fraction remaining by the total ﬂuorescence
recovery from serial bleeding (with background subtraction of
an untreated control blood sample for autoﬂuorescence
determination). Necropsy of the treated mice was performed
at 24 h. Organ distribution was determined by quantifying
organ-speciﬁc recovery of ﬂuorescence above an untreated,
autoﬂuorescence control and normalizing that to the injected
dose.
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Tumor Remediation. Xenografts were established by
injecting 0.1 mL of 5 × 107 MDA-MB-468 luciferase-expressing
cells in a 1:1 cell suspension with BD Matrigel basement
membrane matrix. Tracking of solid tumor growth was
monitored by luminescence imaging (Xenogen, Caliper),
where at each time point of interest 0.1 mL of 30 mg/kg D-
luciferin (Caliper) was administered via i.p. injection to the
tumor-bearing mice 15 min prior to imaging (which used an
open luminescence ﬁlter). Quantiﬁcation of tumor size was
done using Living Image Software, where the total radiance of
each tumor was determined by region of interest analysis
around the entire xenograft. Data are presented as the mean ±
SEM (measured in total radiance) of the fold luminescence
change above the baseline pre-treatment tumor size (on the
basis of radiance). Each animal was normalized independently
and then averaged across the entire group (n = 4) for both the
treatment and control groups. Tumor-bearing mice receiving
the dox-loaded PEG-b-PPLG system were given three repeated
systemically administered 0.1 mL doses at 1.5 mg/kg on day
“0” (after 12 days of tumor establishment and growth phase),
10, and 14.
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